• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 20-F/A filed by WORK Medical Technology Group LTD

    3/20/26 4:00:26 PM ET
    $WOK
    Medical/Dental Instruments
    Health Care
    Get the next $WOK alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 20-F/A

    (Amendment No. 1)

     

    ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    OR

     

    ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the fiscal year ended September 30, 2025

     

    OR

     

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    OR

     

    ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of event requiring this shell company report

     

    For the transition period from                 to                

     

    Commission file number: 001-42256

      

    WORK Medical Technology Group LTD

    (Exact name of Registrant as specified in its charter)

      

    N/A

    (Translation of Registrant’s name into English)

     

    Cayman Islands

    (Jurisdiction of incorporation or organization)

     

    Floor 23, No. 2 Tonghuinan Road

    Xiaoshan District, Hangzhou City, Zhejiang Province

    The People’s Republic of China

    +86-571-82613568

    (Address of principal executive offices)

     

    Shuang Wu, Chief Executive Officer

    Telephone: +86-571-82613568

    Email: [email protected]

    Floor 23, No.2 Tonghuinan Road

    Xiaoshan District, Hangzhou City, Zhejiang Province

    The People’s Republic of China

    +86-571-82613568

    (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

     

    Securities registered or to be registered pursuant to Section 12(b) of the Act.

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A Ordinary Shares   WOK   The Nasdaq Stock Market

     

    Securities registered or to be registered pursuant to Section 12(g) of the Act.

     

    None

    (Title of Class)

     

    Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.

     

    None

    (Title of Class)

     

     

     

     

    Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

     

    An aggregate of 95,998,776 Class A Ordinary Shares, par value $0.05 per share, and 7,592,500 Class B Ordinary Shares, par value $0.05 per share, as of September 30, 2025.

     

    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

     

    Yes ☐ No ☒

     

    If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

     

    Yes ☐ No ☒

     

    Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

     

    Yes ☒ No ☐

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

     

    Yes ☒ No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Emerging growth company ☒

     

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

     

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

     

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive- based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

     

    Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

     

    U.S. GAAP ☒ International Financial Reporting Standards as issued by the
    International Accounting Standards Board ☐
    Other ☐

     

    * If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐

     

    If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

     

    (APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

     

    Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

     

    Auditor Name   Auditor Location   Auditor Firm ID
    WWC, P.C.   San Mateo, California   PCAOB ID No. 1171
    HTL International, LLC   Houston, Texas   PCAOB ID No. 7000

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    WORK Medical Technology Group LTD (“we,” “us,” “the Company,” “our” or “WOK”) is filing this Amendment No. 1 to Form 20-F (the “Form 20-F/A”) to its annual report on Form 20-F for the year ended September 30, 2025 (the “Annual Report”), which was originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 30, 2026. The sole purpose of this Form 20-F/A is an exhibit-only filing to amend the Form 20-F to file the Exhibit 15.2 and Exhibit 15.3. No other changes have been made to the Annual Report as amended by Amendment No. 1.

     

    This Form 20-F/A does not reflect events occurring after the filing of the Annual Report and does not modify or update the disclosure therein in any way except as described above. No other changes have been made to the Annual Report. The filing of this Form 20-F/A should not be understood to mean that any statements contained in the Annual Report and this Form 20-F/A, are true or complete as of any date subsequent to the original filing date of the Annual Report. Accordingly, this Form 20-F/A should be read in conjunction with the Annual Report.

     

    Item 19. EXHIBITS

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    15.2*   Consent of WWC, P.C., regarding the incorporation by reference the report dated February 14, 2025 in this Annual Report on Form 20-F
    15.3*   Consent of HTL International, LLC, regarding the incorporation by reference the report dated January 30, 2026 in this Annual Report on Form 20-F
    104*   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    * Filed with this Form 20-F/A

     

    1

     

     

    SIGNATURES

     

    The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

     

      WORK Medical Technology Group LTD
         
      By: /s/ Shuang Wu
        Shuang Wu
        Chief Executive Officer, Director, and
        Chairman of the Board of Directors

     

    Date: March 20, 2026

     

    2

     

    0001929783 true FY 00000 00000 0001929783 2024-10-01 2025-09-30 0001929783 dei:BusinessContactMember 2024-10-01 2025-09-30 0001929783 us-gaap:CommonClassAMember 2025-09-30 0001929783 us-gaap:CommonClassBMember 2025-09-30 xbrli:shares
    Get the next $WOK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WOK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WOK
    SEC Filings

    View All

    Amendment: SEC Form 20-F/A filed by WORK Medical Technology Group LTD

    20-F/A - WORK Medical Technology Group LTD (0001929783) (Filer)

    3/20/26 4:00:26 PM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by WORK Medical Technology Group LTD

    6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

    2/27/26 4:00:38 PM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by WORK Medical Technology Group LTD

    6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

    2/9/26 9:55:09 PM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    $WOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    WORK Medical Grants East China Exclusive Distribution Rights for AI-Automated Blood Cell Morphology Analyzer, Sets RMB10 Million Sales Target for 2026

    Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical", the "Company" or "we"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Medical Treatment Technology Co., Ltd. ("Hunan Saitumofei") has entered into a one-year exclusive distribution agreement (the "Agreement") with Shanghai Benke Medical Technology Co., Ltd. ("Shanghai Benke") to promote and distribute its newly launched AI-Automated Blood Cell Morphology Analyzer (CM-B600) (the "Analyzer") in East China throughout 2026. Th

    12/29/25 9:35:00 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    WORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval for Its AI-Automated Blood Cell Morphology Analyzer

    Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence ("AI")-Automated Human Blood Cell Morphology Analyzer. This regulatory approval represents a milestone in WORK Medical's research and development strategy and is expected to position the Company's

    12/29/25 9:00:00 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025

    Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the "Reverse Stock Split"). The Company's Class A ordinary shares will begin trading on a post-split basis when the market opens on December 29, 2025. The Company's Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "WOK," with a new CUSIP number G9767H125. The Reverse

    12/24/25 11:30:00 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care